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Being currently the second and potentially becoming the first cause of death in North 
America, cancer has been the focus of researchers from various areas of science. 
Chemotherapy is one of the leading treatment options fr treating various types of cancer, 
particularly advanced cancers. Among different chemotherapeutic drugs currently used 
against cancer, cisplatin (CDDP) is considered as one of the most effective and widely used. 
Despite being the most successful drug in cancer chemotherapy, cisplatin has some 
shortcomings that restrict it from being more widely used. More than three decades of 
intensive research has not yet clearly explained why these shortcomings are associated with 
cisplatin treatment. 
 
Using the advanced “Pump-Probe Femtosecond Time-Resolved Transient Absorption Laser 
Spectroscopy” technique to study the reaction dynamics of cisplatin at the molecular level, 
we discovered new findings that make a profound contribution to our understanding of the 
mechanism of activity of CDDP as a very widely used and effective anticancer drug. By 
observing the reaction dynamics of cisplatin both in its reaction with electrons in water, and 
with all four DNA bases, in real time, we shed new light on the issues that have long been 
elusive for the last three decades. 
 
In addition to these two main research goals, we utilized the same methodology to examine 
the reaction dynamics of transplatin, which currently is not a clinically effective drug, despite 
being an isomer of cisplatin. In this part we mainly focused on examining the molecular 
reaction dynamics of transplatin photoactivation caused by UV irradiation. Here, we studied 
the transplatin reaction with electrons in water as well as with four DNA bases. Results 
obtained in this thesis work clearly reveal the mechanism underlying the cytotoxicity 
enhancement of this molecule after it is irradiated by UV radiation. The data obtained by our 
experiments provide a mechanistic understanding of this cytotoxicity enhancement at the 
molecular level. 
  
As the last goal in our research, we compared the explored reaction dynamics of cisplatin 
with its clinically ineffective trans isomer, transplatin. We believe that our understanding of 
one of these isomers, would also contribute to understanding of the other.  The methodology 
we used to examine transplatin was the same as what we used for cisplatin. First, we 
monitored the possible reactions of transplatin with preydrated electrons in water. After this, 
the dynamics of transplatin’s reactions with DNA bases were examined.  
 
For the first time, we directly observed the reactions f cisplatin and discovered that its 
extremely high reactivity with prehydrated electrons happens in an ultrafast process. We also 
showed the order of reactivity of all four DNA bases with cisplatin and transplatin to be       
G > A > C > T. Finally, in comparing cis and trans isomers of DDP, we discovered cisplatin 
to be about 50% more reactive, suggesting why it is much more cytotoxic. In all of these 
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investigations we obtained promising results that revolutionize our understanding of the 
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Cisplatin is one of the most successful and widely used drugs in current cancer 
chemotherapy. The high rate of success in treating some types of cancer, such as 
testicular cancer, has established a key role for this drug in any cancer chemotherapeutic 
treatment plan. Despite being one of the most promising aticancer drugs ever 
discovered, cisplatin also has very severe shortcomings that have raised some concerns in 
regard to more widespread use of it in chemotherapy. The two main shortcomings of 
cisplatin are its toxic side effects and drug resistance. Extensive research that aimed to 
understand the exact mechanism of these severe drawbacks has not been very successful 
so far. Traditional methods that have been applied to understand, in detail, the precise 
mechanism of action of this important anticancer drug were also not able to offer 
mechanistic explanations of how this drug reacts at the molecular level and how it 
induces the toxic side effects and also how tumors develop rsistance to it. 
 
In this thesis work we applied the advanced Pump-Probe Femto Second Time Resolved 
Transient Absorption Laser Spectroscopy, which is the most p werful method for real-
time observation of molecular reactions, to directly observe the reaction dynamics of 
cisplatin as well as its clinically ineffective trans isomer transplatin. With this cutting-
edge technique, we were able to look at the reactions of cisplatin and transplatin with 
prehydrated electrons as well as with DNA bases in real time and at the molecular level.  
      
This thesis research presents a first-ever-discovered m chanistic understanding of the 
reaction dynamics of cisplatin and transplatin at the molecular level. The experimental 
discoveries explained in this thesis may greatly contribute to the understanding and 
modification of the course of reactions involved in cisplatin activity. 
 
 
1.1 Cancer and its Current Treatments 
 
Cancer is the name of the disease in which cells divide in an uncontrolled way. This 
abnormal growth of cells may generate a mass of abnormal cells that is called a tumor 
[1].   
 
 
1.1.1 Causes of Cancer  
 
In search for the basic causes of cancer, many theories such as over activation of 
oncogenes, malfunction of cellular growth factors, immune system failure, and 
inactivation of tumor suppressor genes have been proposed. Some external stimuli 
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(carcinogens) like UV radiation, some special chemicals, retroviruses, smoke, and many 
others have also been proven to contribute to cancer [1-2].
 
 
1.1.2 Cancer Treatments 
 
Currently, the major modalities of cancer treatment are surgery, radiotherapy and 
chemotherapy, while photodynamic therapy (PDT) is emerging as a relatively new 
cancer therapy.  Besides these major treatment methods, other minor modalities such as 






Surgery is one of the chief forms of treatment for malignant as well as benign tumors. 
After new developments of surgical methods, this modality is being widely used in 
cancer therapy not only as a means of cure, but also for biopsies, palliative treatment, 
laparotomy and removal of endocrine glands to modify the hormonal status and 
suppression of pain by neurosurgical procedures [1,3]. 
 
This treatment modality has some disadvantages as well. One of the biggest issues in 
cancer surgery is that if the disease has progressed to the systemic stage, surgery cannot 
offer a complete cure for it. The effectiveness of surgery is limited not as much by the 
size of the tumor as by its distribution. Even a relatively large tumor can be removed 
completely by surgery if it has not spread to another part of the body. Conversely, a small 
tumor that has dispersed even a few cells to other organs such as the lungs, liver or brain 
cannot be treated successfully by removing the primary tumor alone [1-2]. 
 
The high risk of a surgical operation in some parts of the body is also a huge concern in 





Radiotherapy is the application of radiation in order to destroy cancer cells. The use of 
radiation in therapy began very quickly (within months) after the discovery of the X-ray 
by Roentgen [1,3]. Radiotherapy of cancer is being applied for both curative and 
palliative purposes. 
 
Various types of radiation sources have been used for cancer radiotherapy such as X-rays, 
gamma rays, electron beams, neutron beams, proton beams, and ultrasound [3]. 
 
The main shortcoming of cancer radiation therapy is that i  requires very complicated 
delivery methods in order to save the normal cells, while kil ing tumor cells. Radiation 




Another main concern raised by this method is that patients are usually scanned by an 
imaging method in order that their tumor contours, needed for radiotherapy delivery, be 
obtained. Then, the special treatment and radiation fractionation plan is tailored to them, 
but unfortunately, by the time they go to the clinic to receive the radiation, which is 
within weeks in the best cases, the tumor position and shape s changed and the contour 





Chemotherapy, which is the treatment of cancer by the application of drugs, is another 
modality of cancer treatment, especially used for advanced cancer that has spread [1].  
Chemotherapy’s effectiveness depends on the nature of thecanc r cell. In the process of 
becoming cancerous, the tumor cell is no longer subject to the principles that control the 
growth of a normal cell [2]. The cancer cell has changed some of its metabolic properties 
and may possess quantitatively different nutritional requi ments or different enzymatic 
processes, compared to normal cells. In many respects, therefore, it acts in the same way 
as do foreign invaders such as bacteria, parasites, or viruses [2,4]. Although cancer cells 
differ somewhat from normal cells in their nutritional requirements, unfortunately they do 
not differ from other human cells as much as bacteria or fungi do [4]. In fighting parasitic 
or bacterial diseases, qualitative differences in metabolism between the parasite and the 
host will often allow the infecting organism to be killed by drug levels that are harmless 
to the patient [3-4].  
 
Differences between the metabolism of cancer cells and healthy cells, on the other hand, 
appear to be quantitative rather than qualitative, so that the amount of therapy given is 
limited by the tolerance of the patient’s most sensitive cells. Because there are indeed 
small quantitative differences, nutritional requirements that differ in degree, it is possible 
for just the right dose of a compound to kill the cancer lls without irreversibly 
damaging the normal cells [3]. 
 
The logical approach, then, to finding new chemical agents active against cancer would 
be to find differences between the normal cell and the cancer cell that could be exploited 
in designing compounds to kill specifically the cancer cell. This rational approach, 
however, has not so far been of great clinical benefit. In general, the active drugs have 
been discovered on an empirical or observational basis [4]. These compounds have 
demonstrated activity against tumors in tissue culture or in mice, and their actual 
mechanism of action has often been investigated years after discovery of their activity 
[4]. Cisplatin is a very good example of a compound that demonstrates this principle.  
 
A certain amount of this empirical work, however, hasd a rational basis. When certain 
compounds have shown beneficial effects, many closely related derivatives have been 




The development of cells resistant to any single agent is a major problem in using 
chemotherapeutic agents, so combination chemotherapy, which is applying various 
chemotherapeutic anticancer drugs at the same time, has been developed to improve this 
problem [3-4]. Therefore in combination chemotherapy, the cancer cells resistant to one 
of the chemicals can still be killed by the other drugs, because the chance of a cell’s 
developing resistance simultaneously to all drugs in a combination is very small. 
 
There is usually no cross-resistance between different types of agents with different 
mechanisms of action. For example, a leukemic cell that develops resistance to 
mercaptopurine may still be responsive to methotrexate, cytaxan, vincristine, or 
adriamycin, and vice versa [3].  
 
 
Treatment Limitations in Chemotherapy 
 
Chemotherapy treatment is limited not as much by the sprad of the disease, as by its 
total mass. Although anticancer drugs penetrate the body and search out any clumps of 
cells that may have lodged in other organs, chemotherapy hs great difficulty in 
destroying all cells in a large tumor [1,3,4]. For example, a single course of therapy, 
pushed to the limit of the patient’s ability to tolerate it, may destroy 99-99.9% of the 
tumor cells. In a large tumor weighing 1 kg and containing 1012 cells, a 99.9% kill would 
still leave a billion (109) living tumor cells. The same treatment, however, used against a 
relatively small clump of cells, 102 or 103, would leave essentially no living cancer cells 
[3-4].  
Unfortunately chemotherapy destroys not only cancer cells, but also many rapidly 
dividing normal body cells such as cells lining the gastrointestinal tract, hair follicles, 
bone marrow cells, and lymphocytes involved in the immune defense system.  This 
destruction of normal cells results in the common side effects of chemotherapy: nausea, 
vomiting, diarrhea, hair loss, and increased susceptibility to infection. The normal cells of 
the body, however, usually recover rapidly from these side effects after the course of 
treatment [3-4]. 
 
Each of the major cancer treatment methods has its own advantages and disadvantages, as 
mentioned above, so in order to tailor the best treatm n  plan for a specific patient, 
physicians try to exploit the advantages of each of these three main treatment modalities 
in order to minimize the shortcomings and side effects of reatment. This has given rise to 
treatment strategies that combine these methods to profit from very special strengths of 
each treatment method [3-4]. 
  
Cisplatin, one of the leading drugs in current cancer chemotherapy, will be discussed in 
greater detail in this chapter.  
 
 




Cisplatin [cis-diamminedichloroplatinum (II)] (also called CDDP) is undoubtedly one of 
the most successful and widely used anticancer drugs introduced into general oncology 
practice [5]. Very strong evidence for this claim is the number of patients who have been 
successfully treated by this drug. For example the overall cure rate for testicular cancer is 
currently more than 90% and is nearly 100% for tumors that are promptly diagnosed [6]. 
 
 
Fig. 1.1 Cisplatin 
 
1.2.1 History  
 
The discovery of cisplatin as an antitumor drug has a very interesting story. CDDP as the 
chemical complex that we know today was first synthesized by a chemist named M. 
Peyrone in 1845. Cisplatin used to be called Peyrone's chloride at the time [7,8]. 
 
Despite its synthesis, cisplatin’s structure was not known until 1893 when a chemistry 
Nobel laureate, Alfred Werner explained its structure in detail. After this, cisplatin did 
not attract any special attention until in the 1960s a Michigan State University’s Physics 
professor named Barnett Rosenberg accidentally discovered that cisplatin can induce 
antitumor effects. In the 1960s, Rosenberg was interested in studying the effects of 
electric fields and electric currents on the growth rate of E.coli (a type of bacteria). For 
this reason, he designed an experiment, in which he put positive and negative electrodes 
in the E.coli medium. Very unexpectedly, he noticed that the E.coli he was studying 
under these conditions kept growing in such a way that their lengths were a couple of 
hundred times longer than usual E.coli under natural circumstances. He then understood 
that his E.coli samples stopped dividing and that’s why they w re getting longer than 
usual, because they kept growing instead of dividing.  
 
At first he thought this effect was merely due to the presence of electric fields in the 
E.coli medium, but more extensive investigations revealed that a platinum-containing 
compound produced by the reaction of the platinum electrode an  NH4Cl solution in the 
presence of light and an electrical current was responsible for inhibiting E.coli from 
division [9]. To confirm his hypothesis, Rosenberg and his colleagues applied their newly 
discovered platinum compounds on some types of tumors in mice [10-11]. These 
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compounds were shown to be very effective against selected tumors and cisplatin was the 
most effective against tumor cells among these platinum-containing compounds. This 
research, first published in Nature in 1969 [12], was a great breakthrough in the history 
of cancer chemotherapy drugs. Phase I of the human clinical trials of CDDP started in 
1971 and cisplatin was approved by Food and Drug Administration (FDA) in 1978 under 
the name Platinol [13]. 
 
 
1.2.2 Types of Cancers Treated with CDDP 
 
Cisplatin has been used against various types of cancers. Although it is especially 
effective against ovarian and testicular cancer, it has also been employed for treating 
cervical, head and neck, esophageal, bladder and small cell lung cancer [14]. 
 
The extensive range of cancer types against which cisplatin has showed promising 
results, has established the key role of this drug as a predominant part in almost all single 
/ combinational chemotherapy treatments.  
 
Typical doses of cisplatin are 100 mg/day for up to five consecutive days, and it is 
usually administered in a series of intravenous injections t  cancer patients [15]. 
 
 
1.2.3 Shortcomings of Cisplatin 
 
In spite of being one of the key drugs in cancer chemotherapy treatment, Cisplatin also 
has two important shortcomings that have caused some cncern about its usage. These 
two drawbacks are its toxic side effects and resistance (both intrinsic and acquired) [16]. 
 
 
1.2.3.1 Toxicity  
 
One of the two major problems that limit more widespread use of cisplatin is the severe 
toxic side effects that CDDP induces.  
 
The toxic side effects of cisplatin treatment mainly includes nephrotoxicity, nausea and 





Nephrotoxicity is among the major dose-limiting effects in cisplatin treatment. It is very 
dose-dependent and unfortunately irreversible in some cases.  
 
Renal damage caused by cisplatin includes tubular degeneratio, loss of brush border and 
mineralization of tubular epithelial cells, all of whic  are cumulative. So, patients are put 
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on regimes of combined hydration and diuretics, which has proved to be substantially 
helpful in reducing the nephrotoxicity of cisplatin treatment [5]. 
 




Nausea and Vomiting 
 
The nausea and vomiting caused by cisplatin is very severe. It occurs within the first two 
hours after administration, and will last anywhere from ¼ day to 3 days. Standard 
antiemetic drugs are therefore prescribed to reduce the severity of the effect. It is the 
severity of this toxic side effect that causes some patients to desist from cisplatin 
treatment even with the addition of antiemetics.  
 
In addition to severe nausea and vomiting, patients experi nc  a loss of appetite and taste, 





Another dose-dependent effect of cisplatin is ototoxicity. Again, it is a cumulative and 
irreversible side effect that becomes more significant when treatment is combined with 
radiation therapy [3]. 
 
The ototoxicity of cisplatin also appears to be most significant in children, who may 
experience loss of balance along with hearing difficulties due to greater sensitivity to the 
drug. These effects usually decrease when the treatment ends, however many patients 
experience irreversible hearing loss in the high frequency range (>4kHz).  
 
 
Blood related issues 
 
Myelosuppression (reduction of bone marrow function) is almost the same as other 
anticancer drugs, however thrombocytopenia (reduction of platelets and thus ability for 
blood to clot) and granulocytopenia (reduction of a class of white cells and thus ability to 
fight off infections), may be observed by days 7-9 and 17-19 after injection, respectively 
[3]. Blood counts fall 1-2 weeks after treatment, therefore patients may become anaemic, 
and susceptible to infections, at least temporarily.  
The extent of blood cell reduction is dependent on the size of the dose and whether other 
drugs are used in conjunction with cisplatin [9].  
 







There are two kinds of tumors resistant to CDDP: 
 
Some tumors such as colorectal and non-small-cell lung ca cers have intrinsic resistance 
to cisplatin, while some other tumors develop resistance after the initial series of 
treatments. Examples of these types are ovarian and small cell lung cancers [18]. 
 
Extensive research has not yet explained the molecular bases of cisplatin resistance in 
any type of cell [19].  Although a biochemical modulation (manipulation of cellular 
biochemical pathways by chemical agents to produce selective enhancement of the 
efficacy of an antitumor drug) of the mechanism of activity of cisplatin was suggested by 
Fuertes et al, in order to overcome cisplatin resistance and also to improve the antitumor 
activity [20], lack of sufficient knowledge about the mechanism of action of        
cisplatin, which is required for this approach, has made this solution less accessible.  
 
Expectedly, decreased apoptosis has been associated with rug resistance in very recent 
studies [21]. 
 
1.3 Cisplatin Derivative Drugs 
Over 3000 cisplatin analogues have been tested as anticancer drug candidates [22-23], 
aimed to reduce either the tumors’ resistance to cisplat n [14, 24] or the severe side 
effects [25], but after all these studies, only 28 platinum compounds could enter Phase I 
clinical trials and unfortunately, most of these candidate drugs have faced various 
difficulties in the clinic [26, 27]. 
 
Among these 28 candidates, only three (carboplatin, oxaliplatin and nedaplatin) are 
currently registered for clinical use [28].  Finally, only one has been approved by the 
FDA: oxaliplatin, for the treatment of colorectal cancer [28]. This means that the real 
mechanism underlying these clinically active anticancer drugs is unknown. Thus, the 
search for novel anticancer drugs by traditional methods has proven to be a difficult and 
inefficient task. 
 
Altogether the importance of cisplatin-like drugs is emphasized by the fact that there is 
hardly any clinical regimen of combination chemotherapy today that does not contain 
cisplatin or another platinum drug [29-32]. 
 
 
1.4 Transplatin, an Isomer of Cisplatin 
 
Transplatin (TDDP) is the trans isomer of cisplatin. Transplatin has exactly the same 
chemical formula (Pt(NH3)2Cl2), but a slightly different ligand coordination. Since the 
chemical composition of these two isomers is similar, many of their physical and 






Fig. 1.2 Transplatin 
 
What makes the story of cisplatin activity very puzzling s the fact that the trans isomer 
(transplatin) is not effective at all while the cis isomer is one of the most effective 
anticancer drugs ever discovered [33-34]. 
 
It has been observed that the cytotoxicity of transplatin in tumor cells is remarkably 
enhanced after irradiation by UVA (~320 nm to ~400 nm) light. The reason for this 
cytotoxicity enhancement has been demonstrated to be due to th  promotion of the loss of 
the second chloride of transplatin, caused by UVA light. It was observed that upon 
photoactivation of transplatin by UVA, bifunctional (mainly interstrand) Cross Links 
(CL) are produced with a considerably higher frequency than in the dark [35]. 
 
 
1.5 The Mechanism of Action of Cisplatin as an Anticancer Drug 
 
It is well known that binding of cisplatin to genomic DNA (gDNA) in the cell nucleus is 
the main reason for its antitumor properties [36]. 
 
The convincing evidence that proves that DNA is the main targe  for cisplatin is the early 
observation that cells deficient in DNA repair are hypersensitive to cisplatin [37-38]. 
 
The damage induced upon binding of cisplatin to DNA triggers structural rearrangements 
that may interfere with normal transcription and/or DNA replication mechanisms [39]. 
Eventually, these disruptions in DNA transcription and/or replication would trigger 




How Does Cisplatin Reach DNA in The Cell? 
 
Besides the unanswered question about the mechanism of binding of cisplatin to DNA 
bases, the series of events that happen to CDDP before it reaches the DNA as its main 
target has also been the subject of controversy. These events include the possible 
interactions that cisplatin may encounter after it isadministered to the body on its way to 
the cells, which may include its binding with enzymes, peptides, etc. After this stage, 
CDDP must penetrate through the cell membrane in order to nter the cell. This part is 
one of the most complicated stages of cisplatin’s travel to the cell’s DNA. Earlier studies 
suggested that the cellular uptake was just a passive diffusion [41-42], but recently this 
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idea has been challenged by researchers who believe they hav  discovered a direct link 
between the cellular management of copper and platinum concentrations [43]. 
 
The last barrier on cisplatin’s way to reach the DNA is the nucleus membrane. Transport 
of cisplatin through the nuclear membrane is very poorly understood, and whether or not 
special nuclear peptides play a role remains uncertain [44]. 
 
 
How Does Platinum Attack DNA? 
 
X-ray crystallography studies have shown that the N7 position of the imidazole rings of 
purine DNA bases (specifically guanine) are the most favored binding site in genomic 
DNA for binding with cisplatin [45]. 
 
Solution studies have approved this preferred binding site as well [46].  
 
Cisplatin binding with DNA happens in two steps. Initially it b nds to the N7 site of 
purine DNA bases (mostly guanine) in order to generate monofunctional DNA adducts. 
Subsequently, most of these monofunctional adducts further react with the N7 position of 
an adjacent purine base to make an intrastrand or interstrand cross-link [47-48]. 
 
No convincing explanation has so far been proposed to justify the fact that cisplatin 
happens to bind with this site of purines (guanine and adenine). The hig r preference of 
cisplatin to bind with guanine over adenine has also remained a mystery.  
 
 
DNA-Cisplatin Adducts Percentages 
 
The reaction of cisplatin with DNA may lead to the formation of various structurally 
different adducts.  
 
It has been found that in cisplatin reactions with DNA in vitro, 60-65% of adducts formed 
are 1,2-d(GpG) intrastrand cross-links and 20-25%  are 1,2-d(ApG) intrastrand cross-
links. Taken together, these account for  ~90% of the total adducts formed. 
 
Minor adducts, that account for the remaining 10%, include 1,3-intrastrand cross-links, 
interstrand cross-links [49], and protein-DNA cross-links [50]. 
 
 
Most Effective Cisplatin-DNA Adduct  
 
There is still debate as to which types of cisplatin-DNA adducts are the most important in 
mediating the cytotoxicity of cis-DDP.  
 
Support for the role of the major 1,2-intrastrand adducts in cisplatin-induced tumor cell 
killing, comes from the fact that the trans isomer of cisplatin, trans-DDP or transplatin 
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(which is clinically inactive), cannot form these adducts as it mainly forms 1,3-intrastrand 
and interstrand DNA cross-links [51]. Some researchers have reported that they have 
observed intrastrand adducts with guanine and adenine in cancer pati nts who were 
successfully treated with CDDP [52].  
 
Further support for the importance of 1,2-intrastrand DNA adducts in cancer cell killing 
comes from the observation that the 1,2-intrastrand adducts are less effectively removed 
from DNA by repair enzymes than 1,3-intrastrand adducts [53-54]. 
 
 
Understanding Cisplatin’s Mechanism of Action  
 
Despite the established fact that the ultimate target of cisplatin is the DNA in cells [55-
56], the exact processes that lead to this binding are not fully known [57].  It is well 
established that before cisplatin binds to DNA bases, at least one of the Pt-Chlorine 
bonds should be broken in order to produce more active specie  that can attack DNA.  
 
Although hydrolysis of cisplatin has been proposed as the main echanism that leads to 
the formation of reactive aqua complexes, mainly [PtCl(H2O)(NH3)2]
+  that can bind with 
DNA bases [58], experimental results do not fully agree with it.  
 
Firstly, the main product of hydrolysis of cisplatin which is [PtCl(H2O)(NH3)2]
+ cannot 
readily bind with two DNA bases, and secondly the other hydrol sis product that might 
be able to bifunctionally bind with DNA bases is [Pt(H2O)2(NH3)2]
2+ which has been 
noted experimentally to have the least chances of being produced in the hydrolysis of 
cisplatin [59].  
 
The rate constant that these experiments have arrived at for the production of 
[Pt(H2O)2(NH3)2]
2+ is in the order of only 10-4 M-1s-1. The real constant rate would be 
even lower than this as this number has been calculated under the higher temperature of 
(45 C) instead of body temperature (37C) and in a solvent that is absent in the human 
body [60]. 
 
The very low rate constant of [Pt(H2O)2(NH3)2]
2+ which is the only hydrolysis product 
able to bind with two DNA bases seems to be inconsistent with the established data that 
bifunctional adducts of cisplatin-DNA are the main products of cisplatin’s reaction with 
DNA bases.  
 
Finding a new anticancer drug is a very costly and time consuming process. It is 
estimated that more than 10 000 compounds need to be screened in order to obtain a new, 
effective anticancer drug [61]. 
 
There is a strong need for a mechanistic understanding of the action of cisplatin-like 
anticancer drugs at the molecular level, which can, in turn, lead to the mechanism-based 
design of new drugs.  Indeed, some researchers have recently predicted that in the next 
decade, improved antitumor drugs will be developed based on the knowledge of the 
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cisplatin-DNA interaction and the binding dynamics and kinetics of these Pt compounds 
to DNA and proteins. 
 
 
1.6 The Major Objectives of this Thesis 
 
The research project for this thesis is to directly address the desperate need for 
understanding the precise mechanism of action of cisplatin at the molecular level. The 
advanced “Femtosecond Pump-Probe Transient Absorption Laser Spectroscopy” 
technique enabled us to perform, for the first time, real-time direct observations of 
cisplatin reactions with electrons, either generated during radiolysis / photolysis of water 
or from an electron donor, the guanine or adenine bases in DNA.   
 
By means of this methodology, we also examined, for the first time, the reaction 
dynamics of transplatin in pure water and also in its reactions with all four types of DNA 
bases, (adenine, guanine, thymine, and cytosine) at the molecular level. In this way we 
could observe the differences that exist between the reaction dynamics of these two 
isomers.   
 
It has been claimed that transplatin becomes cytotoxic when photoactivated by UVA light 
[35]. Since our pump laser pulse is in the UVA region, we also had the privilege of 
directly observing the reaction dynamics of this cytotoxicity enhancement in order to 
offer a better mechanistic understanding of the basis of this photoactivation.     
 
This research is the first of its type and has provided new promising insights into the 
molecular level mechanistic understanding of CDDP activity. 
 
 
1.7 Structure of this Thesis 
 
Following this introduction, the principle of time-resolved femtosecond (fs) laser 
spectroscopy is described in chapter 2. 
 
In chapter 3, the results for the reaction dynamics of cisplatin as an anticancer drug will 
be presented and discussed: we first discuss the very strong ansfer reaction of the 
prehydrated electron to cisplatin, and then examine the reaction dynamics of cisplatin in 
reaction with its final therapeutic targets, the DNA bases. In this chapter, we will also 
provide the first experimental evidence that clearly explains why cisplatin binds with 
guanine and adenine more than with thymine and cytosine and also how this reaction 
takes place in real time. 
  
In chapter 4, we will examine the clinically ineffective trans isomer of cisplatin, i.e., 
transplatin. First, the results for the reaction of transplatin with prehydrated electrons in 
pure water are presented and discussed, followed by the dynamics of transplatin reactions 
with all four different DNA bases. The implication of the results for the observed photo-
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The advanced technique applied for my M. Sc. project is the Pump-Probe Femtosecond 
Time-Resolved Transient Absorption Laser Spectroscopy. This prestigious method of 
experimentation is known as the most powerful technique for real-time observation of 
molecular reactions in solutions [1].  
 
 
2.1 Transition State of a Chemical Reaction 
 
The underlying concept of this technique is simple and direct. Figure 1 below depicts the 
free energy curve of a typical chemical reaction versus time (progression of reaction). As 
one can find in a basic chemistry textbook, in order to start the reaction, the reactants 
(here AB and CD) require a specific amount of energy (activ tion energy, EA). Reactants 
need this energy to overcome the potential barrier of the reaction in order to enter the 
next stage of the reaction which is called the transition state or intermediate state [2]. This 
phase of the reaction is very difficult to investigate s the species formed in this stage are 
extremely unstable and short-lived. The typical life time of transition states is in the time 
orders of picosecond (10-12 s) to femtosecond (10-15 s).  After this phase the reaction will 
proceed and the products will be formed based on what have been made in the transition 




Figure 2.1 Free Energy Curve of a Chemical Reaction 
 
 
Examining the characteristics of the transition state is crucial in understanding the 
dynamics of a chemical reaction. For example, precise knowledge about the complexes 
formed in the intermediate phase of a chemical reaction will give invaluable insight into 
why specific products are formed in that specific reaction. This will enable us to precisely 
modulate a chemical reaction in the way that we want it to proceed [2].   
 
The variety of complexes formed in the transition state of a chemical reaction on one 
hand and the ultrafast nature of the formation and evolution of these complexes in the 
transition state on the other hand make it very complicated to directly study the properties 
of transition states. This was not possible until Professor Zewail invented a technique that 
made it possible to directly examine the dynamics of the transition states of chemical 
reactions. This discovery, for which he received the 1999 Nobel Prize in Chemistry, uses 
femtosecond laser spectroscopy to study the transition states of chemical reactions [3]. 
 
 
2.2 Pump-Probe Femtosecond Transient Laser Spectroscopy     
 
Figure 2.2 schematically illustrates the principle of femtosecond laser spectroscopy. Two 
major components of this technique are pump and probe laser pul s.  
 
The role of the pump laser pulse is to initiate the reaction or to create a reacting species 
such as an electron by giving the specific amount of energy required for a specific 
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reaction of interest in order to get started. By tuning the wavelength of the pump laser 
pulse we can precisely adjust the energy of the pump pulse to be exactly equal to the 
required energy for the reaction of interest to get started either by excitation of the 
specific reactant that absorbs the pump pulse energy or b generation of reactive species 
in the sample such as electrons or radicals.  
 
After initiation of the reaction by a pump laser pulse, a second laser pulse (probe) 
irradiates the sample at specific time delays after th  pump pulse.  The probe laser detects 
the formation of complexes that are in the transition state and also follows their evolution 
with time. Like the pump laser pulse, the wavelength of the probe pulse can be tuned 
from IR to UV. The fact that every single complex in the universe has its own specific 
absorption or fluorescence characteristics (spectroscopic finger prints) enables us to 




Figure 2.2 Schematic diagram of a fs time-resolved laser spectroscopy. 
 
 
The time delay between pump and probe laser pulses starts from zero, where the pump 
and probe pulses arrive at the sample simultaneously, to time delays as long as one 
nanosecond.  
The choice of the desired time resolution in pump-probe las r spectroscopy depends on 
the lifetime of the transition state of the chemical reaction under investigation. In our 
experiments, the time delay between pump and probe pulses were made possible by 
applying a micro stepping motor that could cause optical path differences in the order of 
micro meters (10-6 m) or submicrometer (10-7 m) between pump and probe pulses. 
According to the following calculations, a path differenc  of 1 µm can give rise to a time 
difference in the order of femtoseconds 
  ∆t = 
airC
X∆
~ 1/3 × 10-14 ~ 3.3× 10-15 = 3.3 fs 
(if we suppose the speed of light in air to be same as it is in the vacuum) 
 
So we could record images with time differences in the order of femtoseconds if a laser 
pulse of such a short duration is used. In reality, the typical lifetime of the transition state 
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of a molecular reaction is in the order of picoseconds or longer.  Thus, a time resolution 
of ~0.1 ps is adequate for observation of the transition state.   
 
Our special interest in applying Pump-Probe Femtosecond Time-Resolved Transient 
Absorption Laser Spectroscopy as our methodology for this the is project was to directly 
observe the transition state of the ultrafast electron ransfer (UET) reactions of cisplatin 
and transplatin. This technique is known to be the most ver atile and powerful method for 
these types of observations [1,4]. Real-time knowledge of the transition state of an ET 
reaction can help us in predicting, understanding, and changing the pathway of the 
reaction in the way we like. 
 
 
2.3 Laboratory for Ultrafast Biophotonics (Femtobiology) at the University of 
Waterloo  
 
The spectroscopic experiments of this thesis project were done at the Laboratory for 
Ultrafast Biophotonics (Femtobiology) in the Department of Physics and Astronomy, at 
the University of Waterloo. This laboratory was successfully built by my supervisor Dr. 
Qing-Bin Lu [5, 6]. 
 
In this laboratory, the standard methodology for femtosec nd transient absorption 
experiments has been applied. A Ti:sapphire laser amplifier system is applied as a laser 
source producing pulses with a ~120 femtosecond band width and 1 mJ energy per pulse, 
centered at λ= 800 nm with a repetition rate of 1 kHz. Transient absorbance of as small as 
10-4 of an intermediate reaction species at the very low pump energy of ≤50 nanojoules 
(nJ) and the very low probe energy of ≤1 nJ could be achieved in our  spectroscopic 
studies. 
 
Our laser source was a very sensitive device and having it working in perfect condition 
required a very special and stable laboratory situation, as any changes in the temperature 
or humidity of the laboratory could easily make the laser system unstable and accordingly 
increase the noise level.  
 
In order to tune pump and probe pulses in wavelengths from UV to IR, two optical 
parametric amplifiers (OPA) were applied. OPA is an optical device that allows tuning of 
laser pulses based on the principles of nonlinear optics. In order to avoid the contribution 
from polarization anisotropy due to orientation motions of molecules, we set the 
polarization of pump and probe pulses at the magic angle of 54.7º. 
 
We used pump pulse energies of around 0.1 µJ to 0.3 µJ for the first part of the 
experiments of cisplatin and transplatin (cisplatin ad transplatin reactions with 
prehydrated electrons).  
 
We used a 5 mm quartz cell as the container of all samples we studied. In order to avoid 
any photoproduct accumulation in the quartz cell, we used a magnetic stirring bar inside 




All the instrumentation we used in our spectroscopic studies ( ncluding all the 
electronics, stepping motor, etc.) were connected to a personal computer and were 





1. Polanyi, J.C., & Zewail, A.H. 1995 “Direct observation of the transition state”. 
Acc. Chem. Res. 28, 119-132. 
2. Atkins, P.W. 2006 “Physical Chemistry”. 8th edition, W.H. Freeman and Co., 
New York. 
3. Nobel Prize Foundation Website (for chemistry prize in 1999). 
4. Zewail, A.H. 2000 “Femtochemistry: Atomic-scale dynamics of the chemical 
bond using ultrafast lasers (Nobel lecture)”. Angew. Chem., Int. Ed. 39, 2587-
2631. 
5. Wang, C.R., Hu, A., & Lu, Q.B. 2006 “Direct Observation of the Transition State 
of Ultrafast Electron Transfer Reaction of a Radiosensitizing Drug 
Bromodeoxyuridine”. J. Chem. Phys. (Communication) 124, 241102-241102.  
6. Lu, Q.B. 2007 “Molecular Reaction Mechanisms of Combination Treatments of 
Low-Dose Cisplatin with Radiotherapy and Photodynamic Therapy”. Journal of 





















Molecular Mechanism of Action of Cisplatin 
 
 
In this chapter we present the results of our femtosecond pump-probe laser spectroscopic 
studies of the reaction dynamics of cisplatin (CDDP). First we explain the spectra of pure 
water taken by our technique. After this we discuss the cisplat n spectra in pure water 
solution. Then, the reactions of cisplatin with different DNA bases are presented and 
discussed. This chapter ends with a conclusion section. 
 
 
3.1 Introduction  
 
Electron transfer (ET) is the basis of many reactions in molecular systems of chemical, 
biological, and biomedical significance [1-5].  For example “isotopic exchange reactions” 
were among the very early experiments in chemistry that were explained by electron 
transfer (ET) [1]. Another example is the discovery of the important role of ET in DNA 
damage and its repair mechanisms. For this reason, various bi physical and biochemical 
methods have been applied in order to understand electron transfer (ET) in DNA [2]. 
Photo-oxygenation is another example where ET plays an essential role. It had long been 
thought that photo-oxygenation proceeds via energy-transfer quenching, involving the 
sensitization of oxygen by the sensitizer triplet to form excited singlet oxygen, the 
reactive intermediate. However, several reactions could not be explained by this
mechanism. Recent studies clearly support the claim that elec ron transfer (ET) is the 
basis of such reactions [6]. 
 
Real-time observation of the transition state in an ET reaction may lead to the prediction, 
understanding, and modification of the course of the reaction. Among available 
techniques, time-resolved femtosecond (1 fs = 10-15 s) laser spectroscopy is the most 
powerful technique for direct observation of the reaction transition state and reaction 
dynamics [7-8]. 
 
It has been known that halogen (Cl, Br, and I)-containing molecules have efficient 
dissociative attachment reactions with low energy electrons. These reactions produce a 
halogen anion and a neutral radical [9-12].  
 
It was also discovered by Dr. Lu (my supervisor) and his colleagues that the existence of 
polar molecules such as NH3 can cause large enhancements in dissociative electron 
attachment reactions of halogenated molecules. More specifically, for the induced 
reaction of a chlorine (halogen) containing molecule in the NH3 liquid or solid, they 
proposed a dissociative ET mechanism for the enhancements: 
 




Here e¯ : (NH3)n represents a presolvated electron (epre
-) localized in the small polar 
molecular cluster (NH3)n and ABClx represents a given molecule that contains x chlorine 
atoms [13,14]. 
 
Based on the above findings about electron transfer reactions, it is expected that cisplatin 
(Pt(NH3)2Cl2), will show efficient dissociative attachment reactions with weakly bound 
electrons, as this molecule itself has both two chlorine atoms and two NH3 groups bound 
to a Pt atom. Knowing this, we initially focused our atten ion on the aqueous phase of 
CDDP to study the possibility of any electron transfer (ET) reactions related to this 
molecule.  
 
It has long been known that free electrons can be trapped in polar solvents such as water 
and ammonia. Until the 1970s, much knowledge about solvated electrons had been 
obtained [15]. With the advent of the ultrafast laser spectroscopy, the solvation dynamics 
of electrons in liquid water has been investigated intensely over the past two decades 
[16,17].  It is now well known that electron solvation ccurs through essentially two 
major stages after generation of the electrons by two-photon absorption of UV light in 
pure water [18-20].  
 
It has been discovered that electrons pass through short-lived (<1 ps) transient states 
before becoming fully solvated. Prehydrated electrons are denoted collectively as epr
− 
hereafter. The precise physical nature of these ultrasho t-lived transient states is still 
under investigation [21]. epre
−  is considered to be highly reactive and to play a significa t 
role in radiation-induced reactions of molecules in polar media such as water [21]. For 
example, it has been suggested that epre
− in ice is responsible for the strong enhancement 
of the dissociation of chlorofluorocarbons (CFCs) adsorbed on ice surfaces [22] which is 
greatly related to the formation of the ozone hole in arth's atmosphere [23]. 
 
However, it is very difficult to directly observe the r action of epre
− due to its ultrashort 
lifetime, on the femtosecond time scale.  This was not achieved until very recently.  Our 
group was the first to observe the transition states XdU*− of the ultrafast electron transfer 
(ET) reactions of important radiosensitizers, halo-deoxyuridine (XdU, X=Cl, Br and I), 
with the precursor to the hydrated electron, which is another example that shows the 
importance of epre
− in current research [5].  
 
 
3.2 Transient Absorption Kinetic Trace of Water  
        
Transient absorption kinetic trace of pure water is the starting part in our spectroscopic 
studies. Since all samples we have been working with werestudied in the aqueous phase, 
the water transient absorption kinetic trace is required to provide the base trace from 
which any given kinetic trace can be subtracted in order to get its net kinetic trace. For 
our highly sensitive system, it is much better to use ultrapure water, because in this way 
one can make sure no other unexpected substances, existing in non-pure water, is having 
any effect on the system. In our experiments, we had the privilege of using a 
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BARNSTEAD ultrapure water supplier. Our ultrapure water had the electric resistivity of 
higher than 18 MΩ/cm and Total Organic Carbon (TOC) of less than 1 part per billion 
(ppb). 
 
A typical water spectrum recorded with pump wavelength of 318 nm and probe 
wavelength of 266 nm is shown in Figure 3.1 below. The observed narrow peak at delay 
time zero in the water spectra is not the electron sig al but simply the artificial coherence 
spike, which has been studied previously [24-27].  This non-resonant coherence spike has 
been known to be mainly due to conventional stimulated Raman scattering (SRS) or 
impulsive stimulated Raman scattering (ISRS) [26]. SRS gives a sharp peak in the 
transient signal of the solvent if the difference btween pump and probe frequencies 
matches a vibrational mode in the electronic ground state while in ISRS, an ultrafast 
pump pulse excites low-frequency modes in the electronic ground state of the solvent, 
which leads to the scattering of the probe pulse and then gives rise to a signal at any 
probe wavelength. The intensity of this coherence spike depends linearly on the pump 
power at a certain pump power range. 
 
Despite the complications that the coherence spike imposes on the extraction of reaction 
dynamics from the kinetic traces, measuring the position and the full width at half 
maximum (FWHM) of the peak can be used as a means for direct, in-situ determinations 
of not only the delay time zero but the instrument temporal response, which are otherwise 
difficult to obtain in pump-probe experiments [21].  Due to the fact that the coherence 
spike corresponds to the optimum temporal overlap between pump and probe pulses, the 
delay time zero and the instrument temporal response can be measured. 
 
The procedure in our spectroscopic studies is as follows: we take the spectrum of a given 
complex (in this case cisplatin) in its solvent solutin. Then, we take the spectrum of its 
solvent separately, at the same condition (baseline spectrum, in this case ultrapure water) 
and then subtract the complex spectrum from that of the solvent, (baseline) in order to get 
the net spectrum of the given complex. 
 
Beside the exclusive need for the ultrapure water spectrum as the baseline for our 
spectroscopic studies, we used some other features of water spectra as important criteria 
for other issues that were of great value for us. One of these issues is the evaluation of the 
noise level in our experimentation setup every time we wanted to start taking our 
samples’ spectra.  
 
The laser system, the optical parametric amplifiers and the other optical instruments are 
very sensitive devices and tiny changes of any kind in any part of the system can increase 
the noise level of our scanning. Keeping the noise of the system at the lowest possible 
level was of great importance for us. For instance (as will be discussed later), for our 
studies of the reactions of the DNA bases with cisplatin nd transplatin, we had to obtain 
a sufficient signal to noise ratio even with just one single scan of the sample. This is due 
to the drastic electron-induced reaction in the sample. For this reason, having even an 
intermediate noise level could greatly decrease the quality of our spectra, so working with 
the lowest possible noise level in our system was of extreme importance to us. To achieve 
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a perfect level of noise was not always very easy, a m ny factors such as lab temperature 
and humidity, laser system stability, pulse profile symmetry and alignment, sample type, 
extent and strength of the reaction under study, etc. can all have effects on the signal to 
noise ratio. Thanks to the experimental skills of my supervisor Dr. Lu, we could almost 
always benefit from the lowest possible noise level for such laser systems. As is shown 
below (i.e. Fig. 3.1) we were mostly working with a very low noise level (± 10-4), which 
as far as we are concerned, is considered one of the best noise levels for such systems in 
the world. 
 
Whenever the sample under our spectroscopic studies was undergoi g a very strong 
reaction, rapid fluctuations were usually seen during the scanning of their spectra. These 
fluctuations are basically different in nature from the systemic noise of the instruments, 
because if you replace the sample by pure water and take the spectrum of water with the 
same setup of the instruments, you might see that the nois level is even perfect (± 10 -4). 
This means that these two concepts of instrumentation noise and fluctuations caused by 
strong reactions can easily be mixed up together. So if you evaluate the noise level of the 
system based on the fluctuations of the sample you are ex mining, you might be greatly 
misled. For this reason, looking at the transient absorption spectra of pure water in every 
experimental run is the best possible way to evaluate the level of noise in the system in 
that special condition. 
 
The other important criterion for which water spectra were used is double checking the 
cleanness of the samples’ containers (quartz cells).  In particular, to clean the cell in 
which a cycle of the electron-induced drastic reaction of cisplatin has occurred is not a 
trivial, but a challenging task. The pump-probe femtosecond laser scanning system is a 
very sensitive technique, so we had to make sure all the equipment we were using was 
clean. In many cases, if the cell, in which we hold the samples, was not as clean as it 
should be, its water spectrum would change depending on how unclean it was. The water 
kinetic trace is very sensitive to the cleanness of the cell, thus we profited from this 
property as one of our cleanness assurance tests in addition to other checks we made for 
cleanness evaluations of our cell-washing procedures. 
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Figure 3.1 Femtosecond transient absorption spectrum of water, pumped at 318 nm and probed at 
266 nm.  
 
 
3.3 Experiments on Electron-Transfer Reaction of Cisplatin with Prehydrated 
Electron in Water 
 
As mentioned earlier in the introduction of this chapter, cisplatin, a small molecule in 
which two NH3 groups and two chlorine atoms are bound to a Pt atom, is expected to 
have very efficient dissociative attachment reactions with weakly bound electrons. In this 
thesis work, the results of the first time-resolved f mtosecond laser spectroscopic study 
of the molecular reaction mechanism of cisplatin as an effective chemotherapeutic drug is 
reported. Our results discover the high reactivity of CDDP with weakly bound 
prehydrated electrons.   
 
The existence of water in the cell medium where cisplatin becomes reactive and binds to 




3.3.1 Experimental Details 
 
To examine the reactivity of cisplatin with electrons, we set up our femtosecond time-
resolved laser spectroscopic system with the proper adjustments in order to see the real 
time reaction dynamics of cisplatin in aqueous phase. Pump-Probe Femtosecond Time-
Resolved Transient Absorption Laser Spectroscopy is one of the most precise and 





























                     
Figure 3.2 Static UV-Visible Absorption Spectrum of Cisplatin [28]. 
 
 
We tuned the pump laser to the wavelength of 318 nm and the prob laser was set at 266 
nm. The choice of 318 nm for the pump laser comes from the fact that prehydrated 
electrons can be produced via two-photon excitation of water t this wavelength with 
pump pulse energies of 0.15 µJ to 0.3 µJ [5,21].  
 
The best species we could probe during our cisplatin spectroscopic experiments was 
cisplatin in its ground state. Cisplatin has no functional group capable of absorbing UV. 
This is shown above in its “UV-Visible Static Absorption Spectrum” (Fig. 3.2). In fact, 
cisplatin has an absorption band extending up to 350 nm and the major absorption peak is 
located at below 200 nm [28].  
 
In general, the absorption wavelengths of the transition anionic states of halogenated 
molecules (cisplatin in our case) are slightly larger than those of their ground-state parent 
molecules, but they have much weaker signals compared to their parent molecules [5]. 
 
In order to observe cisplatin in its ground state, we set the probe laser at 266 nm because 
cisplatin has a local absorption maximum at this probe wavelength (Fig. 3.2). The 
cisplatin molecule will leave its ground state either upon direct absorption of pump pulse 
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or upon attack of excited electrons, so the parent cisplatin molecules will be depleted in 
the solution and this will give rise to the observation of the negative transient absorption 
signals of cisplatin. This monitoring enabled us to precisely follow the amount of 
cisplatin in the sample. 
 
 
3.3.2 Results and Discussion   
 
Figure 3.3 shows the transient absorption kinetic trace of the cisplatin solution (2.0 mM) 




Figure 3.3 Femtosecond Transient Absorption Spectra of Cisplatin at Various Pump Pulse 
Energies with Pump at 318 nm and Probe at 266 nm. The solid line with a sharp spike at time 
zero is the spectrum for the pure water obtained at the highest pump pulse energy of 300 nJ [28]. 
 
As you can see from the above spectrum, the spectral lines of the 100 nJ/pulse and the 
140 nJ/pulse are almost flat, indicating that the amount of cisplatin has remained constant 
for pump pulse energies below 140 nJ. Sudden excitation of cisplatin by the pump pulse 
at 318 nm causes the photobleaching that is seen in the vicinity of t me zero and the small 
positive signal in the first few picoseconds is due to the CDDP excited state (CDDP*). 
 
Interestingly, the depletion of cisplatin was observed as the pump pulse energy was 
increased to a certain level where a considerable amount of electrons could be generated. 
At the pump energy of 200 nJ per pulse, a clear depletion of cisplatin was observed and 
as we increased the pump pulse energy to higher values the transient absorption signal of 
the cisplatin became even more negative, indicating that more CDDP molecules are 




The electrons that are generated by two-UV-photon excitation of water are believed to be 
captured by cisplatin. These electrons break one or both of the Pt─Cl bonds and produce 
cisplatin reactive radicals, either Pt(NH3) 2Cl
· or Pt(NH3)·. Chlorine ions (Cl-) are also 
released in these reactions. We believe these reactive radicals are responsible for the 
cytotoxicity of cisplatin. There are two leaving Cl
-
 groups in cisplatin, so ET reactions 
happen in two steps. These steps are shown by the following chemical equations:   
 
    (2-a)         ep
- 
 + Pt(NH3)2Cl2 →     [Pt(NH3) 2Cl2]
 *-
    →  Cl
-
  + Pt(NH3) 2Cl
·
 
    (2-b)         ep
- 
+ Pt(NH3)2Cl   →      [Pt(NH3)2Cl]*-       →  Cl
-
  + Pt(NH3)
·        
 
 
A cisplatin molecule can lose its chlorine atoms either by two-step attachments of two 
electrons to cisplatin that releases one Cl¯ ion in each step (single-electron attachment 
process) or by a one-step two-electron process releasing two Cl̄  ions simultaneously. 
The quadratic dependence of the CDDP depletion on the pump pulse energy is a 
characteristic of the first process while the second process will lead to a quadruple 
dependence.  The results shown in Figure 3.3 reveal a relationship between quadratic and 
quadruple dependencies of the cisplatin depletion signal on the pump pulse energy, 
indicating that both single-electron and double-electron tra sfer processes take place. 
 
To have a clearer view of the formation dynamics of CDDP*¯  as well as CDDP in its 
ground state, we can remove the CDDP* signals from the spectrum of figure 3.3.  The 
fact that the CDDP* signal linearly depends on pump pulse energy enables us to remove 
its signals by subtracting the (d) curve (300 nJ/pulse) from the tripled of (a) curve (100 






Figure 3.4 Corrected Transient Absorption Spectrum of Cisplatin [28]. 
 
 
The transition anionic state of cisplatin (CDDP*-) is now clearly recognizable in the 
decay part of the negative signal in the first 20 ps. This decay overlaps with the negative 
depletion signal of the cisplatin molecules in their ground state. 
 
 
Ultrafast Electron Transfer 
 
It was observed (Figure 3.4) that the rise time of the signal (the formation time of 
CDDP*), is clearly within a picosecond (10-12 s) after two photon excitation of water by 
the pump pulse. This time interval is equal to the lifetim  (≤ 1 ps) of prehydrated 
electrons [21, 29].  This observation proves that cisplatin shows a high reactivity with 
weakly bound prehydrated electrons in water. 
  
By running the experiments up to this point, our results experimentally showed the 
existence and dynamics of electron transfer reactions of presolvated electrons in water to 
cisplatin. In the next stage, we will proceed to study the reaction mechanisms of cisplatin 
with different DNA bases.  
 
 
3.4 Experiments on Electron-Transfer Reactions of Cisplatin with DNA Nucleotides 
 
In the second part of our experiments, we were interested in xamining the dynamics of 
cisplatin, (and in the next chapter, of its clinically ineffective trans isomer, Transplatin) 
reactions with all four mononucleotides, namely, adenine (2'-deoxyadenosine- 5'-
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monophosphate or dAMP), guanine (2'-deoxyguanosine 5'-monophosphate or dGMP), 
thymine (dTMP), and cytosine (dCMP). These nucleotides were purchased from Sigma-
Aldrich. 
 
The structure of the DNA bases adenine and guanine are very similar to each other and 
both are called purines. The structure of cytosine and thymine are also very similar to 
each other and then are called pyrimidines. Figure 3.5 shows the chemical structure of all 











(b) Pyrimidines  
 
Cytosine                 Thymine 
 
 
Fig. 3.5 All Four Types of DNA Nucleotides (a) Purines, (b) Pyrimidines 
 
 
The importance of this part of our experiments comes from the established fact that DNA 
is the final target of cisplatin, and more importantly, this DNA binding is known to be the 
main reason for the cytotoxic effects of cisplatin. 
 
 




In order to complete this part of our experiments, we had to change the wavelength of the 
probe pulse as well as the energy of the pump pulse.  
 
The probe wavelength had to be changed from 266 nm to 333 nm because the DNA bases 
have strong absorption in the 266 nm region and using this probe wavelength would have 
caused some undesired consequences such as  
 
1. Damaging DNA bases while scanning the spectrum 
2. Exciting DNA bases and possibly deviating the reaction path from the natural one 
and consequently misleading us from making rational judgments about the 
reaction characteristics 
3. Preventing us from making precise conclusions about the cisplatin content in the 
sample during scanning. This is due to the overlapping absorption of cisplatin and 
DNA bases at 266 nm. As mentioned earlier in this chapter, w  set the 266 nm 
probe to monitor the amount of cisplatin in the sample, so if DNA bases absorb 
some parts of the probe as well, making precise inferences concerning the probe 
signal would be very difficult as the absorption of these two species will be mixed 
up.  
 
In order to avoid these problems, we chose 333 nm for the probe laser pulse. Cisplatin 
still has detectable absorption in this wavelength while DNA bases have no absorption at 
333 nm. 
 
The second change we made in our spectroscopic system was keeping the pump pulse 
energy at energy levels below 140 nJ/pulse in these experiments so that no electron could 
be produced via the two-UV-photon excitation of water, as seen in the spectrum for the 
pure CDDP without the presence of DNA nucleotides (Fig 3.3). This was because we 
were interested in monitoring the reactions of cisplatin with electrons that are exclusively 
from the ground-state of DNA bases. For this purpose, a low pump power was used and 


























Probe- Pump Delay Time (ps)
                  Pump Power  = 25 µW
                    Pump Wavlength = 318 nm 
                Probe Wavelength = 333 nm
                Concent. = [CDDP = 2mM]
 
Fig. 3.6 Femtosecond transient absorption spectrum of water (black line) and also 2 mM CDDP in 
pure water (red line) pumped at 318 nm and probed at 333 nm. 
 
 
A cisplatin solution with 2 mM concentration was prepared as before. According to the 
procedures of doing our experiments, we first obtained the transient absorption spectrum 
of the base line (in our case, ultrapure water). Then, we took the transient spectrum of 
cisplatin in pure water. After this, a fresh sample of cisplatin was added to the specific 
DNA nucleotides. Concentration of the cisplatin and the base was kept at 2 mM for all 
experiments. At the end, their spectra were subtracted from H2O’s spectrum in order to 
get their net spectra.   
 
 




Guanine was the first DNA nucleotide whose reactions with cisplatin were studied. This 
base is considered the most important base in reaction with cisplatin as previous studies 
such as x-ray crystallography proved dominant binding of cisplat n to it [30]. 
 
After adding guanine to cisplatin, the reaction started very r adily and cisplatin was 
greatly depleted in the solution. Here, unlike the case for cisplatin, alone in the solution, 
we could see that guanine reacted greatly with the drug in such a way that after 
subtraction of its spectrum from the baseline, a sharply decreasing negative transient 
absorption (representing the cisplatin content) was observed. The cisplatin reaction with 
guanine proceeded so strongly that every successive scan that we recorded, was about 
30% changed from the preceding one and this trend continued for more than 10 scans. 
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This issue forced us to suffice to one single scan in order to be more precise in our 
experiments of cisplatin with DNA bases. Thus, we scanned our samples one time and 
then continued the experiments with a fresh sample in a new cell.  
 
The strong depletion of the transient absorption signal of this reaction (Fig. 3.7) clearly 
shows the strong reaction of cisplatin with guanine. 
 
 






























Pump = 318 nm, Probe = 333 nm
  Power = 25 µW  Concent.=  [CDDP = 2mM]
   [dGMP = dAMP = dCMP = dTMP = 2mM]
                    
 
Fig. 3.7 Femtosecond transient absorption spectrum of 2 mM Cisplatin with 2mM solution of all 4 
DNA bases (Cytosine, Thymine, Guanine, and Adenine) in water, pumped at 318 nm and probed 
at 266 nm. 
 
 
The negative transient absorption signal (the amount of cisplatin depletion) was recorded 








After guanine, we investigated the reaction of cisplatin with the DNA base cytosine. This 
base did not show any significant reaction with cisplatin nd the amount of CDDP 
depletion was so small that we were persuaded that the reaction is negligible. The flat line 





In our series of investigating all four DNA bases’ reactions with cisplatin, we next looked 
at the reactions of the other purine base (adenine). The reaction of cisplatin with adenine 
was a strong reaction. Although it was not as strong as u nine’s reaction with cisplatin, 
it was much stronger than with cytosine.  The strength of the adenine reaction with 
cisplatin was observed as it was expected. Being a purine and structurally very similar to 
guanine, adenine was expected to show fairly high reactivity with cisplatin.  
 
The amount of depletion of adenine was about 1.5× 0-3 which is around 50% lower than 
that of guanine, meaning that guanine’s reaction with cisplatin proceeds in a way that is 
almost two times stronger than cisplatin’s reaction with adenine. 
 
Each successive scan of the adenine spectrum sharply varied with respect to the previous 
one and the difference was observed to be more than 30% on average. This also 





Finally, we examined the combination of cisplatin with the last DNA base, thymine. We 
could hardly see any reaction happening between thymine and cisplatin, as a very tiny 
amount of cisplatin was used up and reacted with the thymine. The amount of thymine 
depletion was the lowest of all four DNA bases. It was even slightly lower than the 
cytosine depletion, although the spectral lines of these two bases overlapped in some 
regions of the spectrum. The mixture of cisplatin and thymine was so stable that, unlike 
the guanine and adenine cases, each successive scan of its spectrum was almost exactly 
the same as the previous one. As seen in figure 3.7, the thymine absorption signal is 
almost a flat line, slightly lower than the cisplatin spectral line. This characteristic clearly 
reveals there is no considerable electron transfer reaction taking place between CDDP 
and this DNA base.  
 
Another characteristic of the thymine spectral line in the transient absorption spectrum is 
that it is very smooth and not many fluctuations can be seen in it. This can also give a 
qualitative measure of the weakness of this reaction compared with guanine and adenine 







For the first time we explored new findings concerning the reaction dynamics of 
cisplatin, and shed light on some of the confusions that existed in the field regarding the 
mechanism of action of this leading drug at the molecular level and also the dynamics of 
its bindings with different DNA bases.  
 
Our ultrafast high sensitivity real-time femtosecond laser spectroscopy technique is one 
of the most direct methods to look at the heart of the c emical reactions (transition states) 
in order to precisely examine the dynamics of the reaction in real time while the reaction 
is proceeding.   
 
One of the first things that we observed during our experiments on cisplatin is that CDDP 
is a very strong electron capturer and strongly reacts with electrons, either generated 
during radiolysis / photolysis of water or from an electron donor such as guanine / 
adenine bases in DNA. 
 
Second in our findings is that the electron transfer (ET) reaction between cisplatin and 
prehydrated electrons occurs in an ultrafast process. This electron transfer occurring in 
less than 1 picosecond (10-12 sec) is convincing evidence that the transferred electrons are 
prehydrated. This is very clearly seen in the spectra of cisplatin in pure water (Fig. 3.3). 
 
One of the most important discoveries that our results clearly show is that among all four 
DNA bases, guanine shows the greatest preference for binding with cisplatin and its 
reaction with this drug is the strongest. The fact that cisplatin happens to bind mostly 
with guanine in the body after it is given to cancer patients, was already discovered by 
different methods, but our results provide the first and only experimental evidence that 
explains why this preference exists and also what happens, at the molecular level, that 
causes the guanine base to become the most favored binding site for cisplatin. We have 
now uncovered that this is because guanine is thermodynamically the best electron donor 
among the four DNA bases.  
 
The reaction of cisplatin with guanine is so strong that t e absorption signal in its 
dynamic transient absorption spectrum sharply decreases nd significant depletion of 
cisplatin is observed. This finding was to some extent expected for us, but such a high 
reactivity of cisplatin with guanine was surprising. 
  
Our results yielded further support by providing experimental proofs about the order of 
the reactivity of different DNA bases (all four types) with cisplatin. Our experimental 
results show the order of reactivity of different DNA bases with CDDP is guanine > 
adenine > cytosine > thymine. Very interestingly, this order is exactly the same as the 
order of the thermodynamical preference of electron doati n among the four DNA 
bases, which was already known [31].  This fact offers a very persuasive confirmation 
and a means of double checking our findings. We found cisplatin to be a very strong 
electron capturer and the order that we obtained for the pref rence of all four DNA bases 
to react with cisplatin is exactly what was logically expected. 
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The real-time and ultrafast examinations of the reaction dynamics and spectroscopic 
properties of one of the most widely used anticancer drugs, cisplatin, at the molecular 
level, with and without its final target (DNA bases) that were accomplished in our 
laboratory enable us to make a very promising contribution to a better understanding of 
the mechanism of action of this most important anticancer drug. We believe that the 
important progress we made in discovering cisplatin’s electron reactivity will play an 
important role in the universal efforts to improve the shortcomings of this drug.  
 
The cutting-edge research done in our lab will have great influe ces in this area of 
pharmaceutical research and we are very optimistic that our findings represent a big step 
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Molecular Mechanism of Action of Transplatin 
 
 
In chapter 3, the first-ever results of femtosecond pump-probe transient laser 
spectroscopic studies of the molecular reaction dynamics of cisplatin (CDDP) as one of 
the most widely used chemotherapeutic anticancer drugs were pr sented and discussed. 
In this chapter, we present the results obtained from the femtosecond time resolved laser 
spectroscopy experiments of CDDP’s trans isomer, i.e. transplatin (TDDP).  Here, the 
major objective was to directly observe the molecular mechanism of transplatin 
cytotoxicity enhancement upon UV photoactivation. These studies include the molecular 
reaction dynamics of transplatin in pure water as wellas with DNA bases.  
 
The methodology applied in these experiments is exactly the same as that applied to 
cisplatin (explained in chapter 3).  The last section of this chapter contains the 
conclusions drawn from our results.  
 
 
4.1 Introduction  
 
As mentioned in chapter 1, transplatin does not show any cytotoxicity and is clinically an 
ineffective compound, but very recently it has been observed that the cytotoxicity of 
transplatin in tumor cells can be remarkably enhanced upon irradiation by UVA (~320 
nm to ~400 nm) light [1]. The reason for this cytotoxicity enhancement has been 
demonstrated to be due to the promotion of the removal of the second chloride of 
transplatin by UVA light. It was observed that upon photoac ivation of transplatin by 
UVA, bifunctional DNA adducts of transplatin (mainly interstrand cross links) are 
produced with a considerably higher frequency than in the dark [2].  The main research 
objective of this chapter is to reveal the mechanism underlying the enhancement of the 
cytotoxicity of transplatin once it is photoactivated.    
 
Applying UV radiation as the pump laser pulse (318 nm) in our experiments, we were 
able to look at the photoactivation reactions of transplatin with DNA bases as its 
pharmaceutical target. If we understand the molecular dynamics of transplatin’s reactions 
with DNA bases after it is photoactivated by UVA irradi tion, there may be a hope for it 
to enter clinical trials and become an effective antica cer drug in the near future.   
 
Our other research objective in conducting the transplatin experiments was to compare 
the reaction dynamics of transplatin with its clinically effective cis isomer i.e. Cisplatin 
(CDDP). Since these two molecules are isomers, our understanding of each one of them 
will greatly contribute to understanding of the other. We believe comparing the properties 
of these two isomers will lead to profound insights that m y enable us to expand our 
knowledge of the shortcomings of cisplatin and consequently able us to improve it. For 
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this reason, we first compare these two isomers in terms of their reactivity with 
prehydrated electrons in pure water.  
 
The interest of research on properties of transplatin comes from the mysterious fact that 
the trans isomer does not show any antitumor effects while the cis isomer (cisplatin), is 
one of the strongest antitumor drugs ever known [3,4].  Thepuzzling fact that transplatin, 
despite having a very similar chemical composition, does not induce any cytotoxicity has 
attracted scientists’ attention for many years. In the following sections we report the first 
ever results on transplatin molecular reactions obtained by means of femtosecond time 
resolved transient laser spectroscopy.   
 
 
4.2 Experiments on Electron-Transfer Reaction of Transplatin with Prehydrated 
Electrons in Water 
 
Transplatin has the same chemical formula as cisplat n and the difference in their 
chemical structure is that in transplatin the Cl atoms and NH3 groups have a trans 
orientation. Based on these close similarities betwen cisplatin and transplatin one could 
speculate that transplatin may also show certain reactivity with the prehydrated electron 
excited by a pump pulse in pure water (just as we observed in the case of cisplatin in the 
last chapter). The obtained results of the femtosecond time-resolved laser spectroscopic 
examination of the molecular reaction mechanism of transplatin as the isomer of cisplatin 
are discussed in this chapter. Our experimental evidences reval the reactivity of TDDP 
with weakly bound prehydrated electrons.   
 
 
4.2.1 Experimental Details  
 
In order to start our spectroscopic studies of transplatin, we used the same experimental 
setup as we did for cisplatin. Initially, we restricted ourselves to look at the reaction 
dynamics of transplatin in pure water to see any possible electron transfer reaction, as we 
had observed in the case of cisplatin.  
 
Both cisplatin and transplatin were bought in solid phase from Sigma-Aldrich and was 
used as supplied. Both of these two compounds needed to be solved in water before 
spectroscopic studies. Since cisplatin has a much higher wat  solubility (0.253 gr per 
100 gr water) than transplatin (0.036 gr per 100 gr water) [5], preparing its solution took 
much less time than the transplatin solution preparation; we had to put the transplatin 
solution in a heater at 60º C for at least 24 h before the experiments in order to get a well 
solved transplatin solution. Transplatin in stock soluti ns was kept at 2 mM. 
 
We adjusted the wavelength of the pump laser to 318 nm and the probe wavelength to 
266 nm.  As described in the previous chapter, we took the transplatin solution transient 
absorption spectrum and subtracted it from the ultrapure wat r spectrum in order to get 




Various pump pulse energies from 40 nJ to 320 nJ (powers from 10 µW to 80 µW) were 
used in order to see the changes of the reactions with respect to pump pulse energy.  
 
 
4.2.2 Results and Discussion 
 
Transient absorption kinetic trace of the transplatin solution, with 2.0 mM concentration, 
at various pump pulse energies (from 40 nJ to 320 nJ) is shown in Figure 4.1. 
 
No negative transient signal is visible in the spectral lines of 40 nJ/pulse and 120 nJ/pulse 
revealing that for pump pulse energies below 120 nJ/pulse, the amount of transplatin in 
the sample has not changed. The photobleaching observed near the time zero is due the 
abrupt excitation of transplatin by the pump pulse at 318 nm. The small positive signal in 
the first few picoseconds is also caused by the TDDP excited state (TDDP*). 
 
As the pump pulse energy was increased to a certain level, clear depletion of transplatin 
was observed. This is due to the considerable amount of electrons that are produced at 
high pump pulse energies. For example as you can see in the spectra of Figure 4.1 below, 
at the pump energy of 240 nJ per pulse, a significant depletion of transplatin is visible. As 
we increased the pump pulse energy, the transplatin depletion was seen to be increased 
accordingly. This phenomenon was similar to what we observed for cisplatin (described 
in chapter 3).   
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Fig. 4.1   Femtosecond Transient Absorption Spectra of 2 mM transplatin at Various Pump Pulse 





Our experimental evidences revealed the dynamics of electron transfer reactions of 
presolvated electrons with transplatin in water. Our results concerning the reaction 
mechanisms of transplatin with different DNA nucleotides will be discussed in the 
following section.  
 
 
4.3 Experiments on Electron-Transfer Reactions of Transplatin with DNA 
Nucleotides 
 
In this section of our studies we look at the reaction characteristics of transplatin with 
four DNA nucleotides with the pump pulse laser in the UVA region. The details of the 
instrumentation are exactly what were applied in chapter 3 for examining cisplatin 
reactions with DNA nucleotides. The DNA nucleotides used for these experiments were 
exactly the same as those used in chapter three. The results of the reactions of each of the 
different nucleotides with transplatin are explained in the following section.  
 
 
4.3.1 Experimental Details  
 
For our studies of the reaction dynamics of transplatin with DNA bases, the optimum 
pump pulse energy had to be kept so low that no prehydrated electrons were generated 
and consequently no ET reactions could happen between th  electrons and transplatin. 
Thus, the pump pulse energy of ≤ 0.1 µJ (pump power of 25 µW) was used to avoid the 
creation of prehydrated electrons. As shown in Figure 4.2 below, no ET reactions happen 
between the prehydrated electrons and transplatin at this pump pulse energy. The 
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Fig. 4.2 Femtosecond Transient Absorption Spectra of pure water alone (black line) and also with 
transplatin (red line) with Pump at 318 nm and Probe at 333 nm. The pump power is 25 µW.  
 
 
The four mononucleotides adenine (2'-deoxyadenosine- 5'-monophsphate or dAMP), 
guanine (2'-deoxyguanosine 5'-monophosphate or dGMP), thymine (dTMP), and cytosine 
(dCMP) were purchased from Sigma-Aldrich and used as supplied.  
 
 




In our investigation of transplatin reactions with all four DNA bases, we started with 
guanine.  Interestingly the guanine seemed to react with photoactivated transplatin rather 
strongly. The amount of depletion of the transplatin fter the addition of guanine is very 
close to the depletion amount of cisplatin in its reaction with adenine and almost half of 
the reactivity of cisplatin in its reaction with guanine.  
 
This reaction seemed to have some fluctuations (as you see in the spectrum of Fig. 4.3 
below), but they were less than the fluctuations of the reaction of cisplatin with guanine.  
 
While taking the spectra, each scan changed with respect to the previous one, so just as in 
the cisplatin case, we decided to conduct our experiments by taking just a single scan for 
each spectrum of the transplatin in combination with each of the DNA bases. This 
constraint made our procedure more difficult as we had to repeat our scanning many 
times with fresh samples to make sure it was well reproducible. Due to the ultra high 
 
 45 
sensitivity of our experimentation setup, we had to be exceptionally careful in taking the 
spectra, as any tiny change in the system could cause some detectable changes in our 
results. 






































   Pump Wavelength = 316 nm    
   Probe Wavelength = 333 nm
               Pump Power = 25 µW 
         Concent. = [TDDP = 2mM] 
  [dGMP = dAMP=dCMP=dTMP=2mM]
                
 
Fig. 4.3 Femtosecond transient absorption spectrum of 2 mM transplatin with 2mM solution of all 
4 DNA bases (Cytosine, Thymine, Guanine, and Adenine) in water, pumped at 318 nm and 





The cytosine reactivity with photoactivated transplatin was very low. As observed in the 
spectrum of figure 4.3, the decrease in its depletion line is not very detectable. The 
cytosine depletion in its reaction with transplatin was again less than its depletion with 





Adenine is another DNA base which has more importance than cytosine and thymine 
here, because it is expected to show more reactivity. This was exactly what we observed, 
as shown in Figure 4.3. The DNA base adenine showed more preference in binding with 
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transplatin than cytosine. Its depletion amount was almost half of the depletion of 
guanine with transplatin and also half of the depletion amount of adenine in its reaction 
with cisplatin. The reaction of adenine with photoactivated transplatin yielded a smoother 
absorption signal curve (less fluctuations) compared to the fluctuations that were seen in 
its reaction with cisplatin. 




As the final step in the study of the reactivity of different DNA bases with transplatin, we 
finally looked at thymine. This DNA base showed the least reactivity with photoactivated 
transplatin. Basically what we observed was a flat line in its transient absorption 
spectrum (fig. 4.3) representing almost no reaction taking place. This line is so flat that 
the amount of transplatin depletion it suggests is almost in the order of the errors of our 
experiments and one can hardly claim that any reaction is actually happening between 
thymine and transplatin. Thymine and cytosine are very similar in terms of their 





The results of the reaction mechanism of transplatin have significance in that transplatin 
can become cytotoxic upon UV irradiation. Results obtained i  our experiments clearly 
support this enhancement. Our experiments provide evidence for the molecular 
mechanism of this cytotoxicity enhancement. The reactions of UV-irradiated transplatin 
with DNA mono nucleotides clearly support the idea that photoactivation can turn the 
ineffective parent transplatin molecule to an effective and cytotoxic compound. 
    
A further goal of this chapter is to discuss the similarit es and dissimilarities of transplatin 
and cisplatin, based on our experiments. These will be further discussed in what follows.  
 
In finding an answer to our questions regarding the possibility of electron transfers to 
transplatin, our data showed that this molecule is also n electron capturer and can react 
with the excited prehydrated electrons in water. The existence of the electron-attracting 
nature of transplatin makes this molecule similar to cisplatin, but they differ in that 
cisplatin is a stronger electron capturer than transpl tin. 
 
The ultrafast electron transfer happening at ≤ 1 ps clearly shows that the electrons 
reacting with transplatin are prehydrated electrons, as they have exactly the same life 
time [6]. 
 
Transplatin showed the same order of preference for binding with the different DNA 
bases as cisplatin, i.e. guanine > adenine > cytosine > thymine. This finding was expected 
as transplatin has also been proved to be an electron capturer and this order of the DNA 
bases is just the order of their thermodynamical preference for donating an electron [7]. 




Comparing the reaction dynamics of transplatin and cisplatin based on their reactions 
with DNA bases may greatly extend our knowledge of the mechanism of activity of 
cisplatin. 
 
In the case of guanine, the depletion of cisplatin was almost two times more than the 
depletion of transplatin in its reaction with guanine. Besides that, the depletion line 
(negative absorption signal) of the reaction of guanine with cisplatin seems to show more 
fluctuations which itself is a measure that qualitatively shows the strength of the reaction.  
 
By comparing the dynamics of the reactions of the other purine DNA base (adenine) with 
transplatin and cisplatin, different parts of the scenario fit together better. Just like the 
case of guanine, the amount of transplatin depletion in its reaction with adenine is half of 
the depletion amount of cisplatin while reacting with adenine. The negative absorption 
signal in the spectrum of transplatin with adenine shows fe er fluctuations than what was 
observed in the reaction of adenine with cisplatin.  It might be interesting that the 
depletion amount of adenine in its reaction with cisplatin is very close to the depletion 
amount of guanine in its reaction with transplatin, signifyi g that more reactivity of one 
DNA base (guanine) is compensated by less reactivity of the electron absorber 
(transplatin) in such a way that the total combination has almost the same depletion 
amount.  
 
The two other DNA bases, thymine and cytosine (both pyrimidines), hardly show any 
reactivity with transplatin. As seen in the transient absorption spectrum of transplatin 
with DNA bases, (fig. 4.3) the spectral lines of thymine and cytosine largely overlap with 
the spectral line of transplatin in such a way that one can hardly assign any reactivity to 
them.   
 
Here, both the cytosine and thymine spectral lines are vey much the same and their 
subtraction from each other will give almost zero difference. The superiority of the 
reactivity of cytosine over thymine observed in their reaction with cisplatin (chapter 
three) is much less pronounced here in their reaction with transplatin.  
   
Based on the results just mentioned, we conclude that cisplatin showed more than 50% 
higher reactivity than its trans isomer, transplatin, in their reactions with purine DNA 
bases, guanine and adenine.  
 
The evidence discussed in this chapter indicates that transplatin has great potential to 
become a UV photoactivated anticancer drug candidate. The rat r high reactivity of 
transplatin with DNA bases guanine and adenine upon UV photoactivation obtained by 
our femtosecond time resolved laser spectroscopy completely supports this hope.  
 
This thesis study suggests that photoactivated transplatin may be explored as a promising 
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We have applied state-of-the-art Pump-Probe Femtosecond Time-Resolved Transient 
Absorption Laser Spectroscopy to investigate the dynamics of cisplatin reactions at the 
molecular level.  For the first time, we revealed the mechanism of action at the true 
molecular level of CDDP, one of the most effective and widely used anticancer drugs. 
We examined the reaction dynamics of cisplatin in its reactions with prehydrated 
electrons in water, as well as with all four types of DNA bases i.e. guanine, adenine, 
thymine, and cytosine.  
 
In the second part of this thesis research project we investigated the characteristics of the 
trans isomer of cisplatin, i.e. transplatin. In the transplatin case, we were especially 
interested in looking at the molecular mechanism of the photoactivation of this molecule 
upon UV irradiation. The data obtained by femtosecond time resolved laser spectroscopy 
clearly explains the dynamics of this cytotoxicity enhancement at the molecular level.   
 
In our investigations of cisplatin, we initially proved tha  cisplatin is an extremely strong 
electron acceptor by looking at its reaction dynamics with prehydrated electrons in water, 
generated by the pump pulse energies greater than 140 nJ at 318 nm. These electron 
transfer reactions proceeded very rapidly and efficiently.   
 
The electron transfer reaction between the electrons produced in water and cisplatin 
happened in an ultrafast process. The formation of cisplatin anionic transient states was 
seen to be within 1 picosecond (10-12 s) which is the same as the life times of prehydrated 
electrons (≤  1 ps) clearly proving the reacting electrons produced in water to be 
prehydrated electrons. The prehydrated electrons are believed to break Pt-Cl bonds that 
finally lead to the production of reactive species Pt(NH3) 
·  or  Pt(NH3) 2Cl 
· that 
contribute to the cytotoxicity of cisplatin. 
 
By establishing the role of prehydrated electrons in the process of activity of cisplatin, we 
pushed forward the investigation of the reaction mechanisms of ci platin with its clinical 
targets which are DNA bases. 
  
In this thesis research work, we reported, for the firstt me, the dynamics of cisplatin’s 
reaction with all four types of DNA bases and proved the order of their reactivity with 
cisplatin to be Guanine > Adenine > Cytosine > Thymine, which is in complete 
agreement with the known thermodynamic preference of electron donation among the 
four DNA bases. 
 
This discovery was an expected consequence of our first observation that cisplatin is a 
strong electron acceptor. Thus, the stronger electron donor a molecule (DNA base) is, the 
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more efficient ET reaction would be expected. As guanine is the strongest electron donor 
with the lowest required energy among the four DNA bases, its reaction with cisplatin 
was observed to be the most effective.  
 
These parts of our research were experimentally very sophi ticated, as the reactions were 
observed to be very strong and drastic. 
 
The reaction of cisplatin with adenine was not seen to be as strong as cisplatin reaction 
with guanine. To be more precise, adenine was observed to be half as reactive compared 
to guanine, but it is still the second reactive base among all four bases. This is again in 
complete accordance with the known statistics of cisplatin binding with DNA bases. 
 
The extent of cisplatin’s reactions with other two bases, cytosine and thymine, were not 
comparable to those of guanine and adenine. Although cytosine showed more reactivity 
than thymine, both of the reactions were so weak that one can hardly relate them to 
cisplatin’s anticancer effects. 
 
For the first time, we provided a mechanistic understanding at the molecular level as to 
why cisplatin binds with DNA bases in the very special order of G > A > C > T. 
 
In our examinations of transplatin, we were focused on investigating the molecular 
reaction dynamics of the UV caused photoactivation. Results obtained in our experiments 
on transplatin well support the cytotoxicity enhancement of his molecule after it is 
irradiated by UV radiation. Our experiments provide evidence for the mechanistic 
understanding of this cytotoxicity enhancement at the molecular level.  
 
The findings obtained concerning transplatin in this thesis study suggest that 
photoactivated transplatin may be explored as a very promising anticancer drug candidate 
for general oncology practice. 
 
Our final research aim was to compare the explored reaction dynamics of cisplatin with 
that of transplatin in order to shed new light on the old mystery of why this isomer is not 
effective despite being so similar to cisplatin.  
 
We obtained experimental evidence, for the first time, to support the order of reactivity of 
photoactivated transplatin with DNA bases being G > A >C  T just as we observed in 
the case of cisplatin. The higher reactivity of DNA bases guanine and adenine with 
cisplatin than with transplatin was the main differenc  that we recorded in comparing 
these two isomers.  
 
According to our obtained data, transplatin showed 50% less r activity than cisplatin in 
reactions with DNA bases. 
 
Beside these mentioned discoveries, we believe this research also contributes to our 
knowledge of the effects of species like NH3 on the enhancement of electron-induced 




All these findings provide a molecular-level mechanistic understanding of cisplatin 
cytotoxicity. The very precise data we achieved by means of our cutting-edge 
experimental method provide the most profound understanding about the dynamics of 
cisplatin and transplatin reactions with DNA as its most important target. We shed new 
light on issues that have long been elusive in the history of cisplatin research, for the last 
four decades. We believe our discoveries will have significant effects in improving the 
therapeutic applications of this exceptional chemotherapeutic drug, such as the 
circumvention of drug resistance and the reduction of toxic side effects. Moreover, our 
findings will have significance for mechanism-based design and development of new 
anticancer drugs in the future. 
 
 
 
